RAV-12

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRAV-12
Drug Alias NameANTI-RAAG12-MABRAV-12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionCell membrane modulatorsImmunostimulantsSignal transduction pathway modulators +[4] 
TargetsDisialoganglioside GD2
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMacrogenics Inc
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank